Your AI-Trained Oncology Knowledge Connection!
In an interview with Targeted OncologyTM, Leslie, assistant professor, Hackensack Meridian School of Medicine, director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs, John Theurer Cancer Center, discussed the CAR T-cell product, brexucabtagene autoleucel, and its influence on both MCL and indolent lymphomas.
Dr Peter Martin discusses the impact of CAR-T cell therapy in patients with MCL and provides a brief review of key efficacy data from the ZUMA-2 trial.
Dr Brian Hill discusses the potential use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma (MCL) and reviews emerging treatment options for patients with MCL.
Brian Hill, MD, discusses the use of CAR T-cell therapy in earlier lines of treatment for mantle cell lymphoma and identifies other novel agents in this setting.
